MXPA04000080A - Metodos de diagnostico de cancer en la vejiga, composiciones y metodos de rastreo de moduladores de cancer en la vejiga. - Google Patents

Metodos de diagnostico de cancer en la vejiga, composiciones y metodos de rastreo de moduladores de cancer en la vejiga.

Info

Publication number
MXPA04000080A
MXPA04000080A MXPA04000080A MXPA04000080A MXPA04000080A MX PA04000080 A MXPA04000080 A MX PA04000080A MX PA04000080 A MXPA04000080 A MX PA04000080A MX PA04000080 A MXPA04000080 A MX PA04000080A MX PA04000080 A MXPA04000080 A MX PA04000080A
Authority
MX
Mexico
Prior art keywords
bladder cancer
diagnostic
regulated
screening methods
whose expression
Prior art date
Application number
MXPA04000080A
Other languages
English (en)
Inventor
H Mack David
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Publication of MXPA04000080A publication Critical patent/MXPA04000080A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

En la presente se describen genes cuya expresion es regulada ascendentemente y regulada descendentemente en cancer de vejiga. Tambien se describen los genes donde la expresion ademas se regula hacia arriba o se regula hacia abajo en celulas cancerosas de vejiga resistentes a farmacos. Se describen metodos y composiciones relacionados que se pueden usar para diagnostico, prognosis, o tratamiento de cancer en la vejiga. Tambien se describen en la presente metodos que se pueden usar para identificar moduladores de cancer en la vejiga.
MXPA04000080A 2001-07-03 2002-07-03 Metodos de diagnostico de cancer en la vejiga, composiciones y metodos de rastreo de moduladores de cancer en la vejiga. MXPA04000080A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US30281401P 2001-07-03 2001-07-03
US31009901P 2001-08-03 2001-08-03
US34370501P 2001-11-08 2001-11-08
US35066601P 2001-11-13 2001-11-13
US37224602P 2002-04-12 2002-04-12
PCT/US2002/021338 WO2003003906A2 (en) 2001-07-03 2002-07-03 Diagnostic and screening methods for bladder cancer

Publications (1)

Publication Number Publication Date
MXPA04000080A true MXPA04000080A (es) 2004-05-21

Family

ID=27540883

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04000080A MXPA04000080A (es) 2001-07-03 2002-07-03 Metodos de diagnostico de cancer en la vejiga, composiciones y metodos de rastreo de moduladores de cancer en la vejiga.

Country Status (7)

Country Link
US (1) US20040076955A1 (es)
EP (1) EP1408811A2 (es)
JP (1) JP2005514908A (es)
AU (1) AU2002316576A1 (es)
CA (1) CA2453098A1 (es)
MX (1) MXPA04000080A (es)
WO (1) WO2003003906A2 (es)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US20040248169A1 (en) * 1999-01-06 2004-12-09 Chondrogene Limited Method for the detection of obesity related gene transcripts in blood
CN1387538A (zh) 1999-01-15 2002-12-25 比奥根公司 针对tweak及tweak受体的拮抗剂和它们在治疗免疫性疾病中的应用
US7358353B2 (en) 2000-08-22 2008-04-15 Agensys, Inc. Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
ES2281437T3 (es) 2000-08-22 2007-10-01 Agensys, Inc. Acido nucleico y proteina correspondiente denominada 158p1d7 util para el tratamiento y la deteccion del cancer de vejiga y otros canceres.
US7208151B2 (en) * 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US20040003418A1 (en) 2001-04-10 2004-01-01 Aya Jakobovits Nucleic acid and corresponding protein entitled 158P3D2 useful in treatment and detection of cancer
US7811575B2 (en) 2001-04-10 2010-10-12 Agensys, Inc. Nucleic acids and corresponding proteins entitled 158P3D2 useful in treatment and detection of cancer
US20030211039A1 (en) * 2001-05-29 2003-11-13 Macina Roberto A. Method of diagnosing, monitoring, staging, imaging and treating colon cancer
WO2003080856A2 (en) * 2002-03-19 2003-10-02 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003086311A2 (en) 2002-04-09 2003-10-23 Biogen, Inc. Methods for treating tweak-related conditions
AU2003263767A1 (en) * 2002-07-03 2004-01-23 Aventis Pasteur Inc. Tumor antigens bfa4 and bcy1 for prevention and/or treatment of cancer
WO2004016733A2 (en) * 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
WO2004040014A2 (en) * 2002-11-01 2004-05-13 Aros Applied Biotechnology Aps Gene expression in biological conditions
JP2007520996A (ja) * 2003-01-15 2007-08-02 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ４４３９０、５４１８１、２１１、５６８７、８８４、１４０５、６３６、４４２１、５４１０、３０９０５、２０４５、１６４０５、１８５６０、２０４７、３３７５１、５２８７２、１４０６３、２０７３９、３２５４４、４３２３９、４４３７３、５１１６４、５３０１０、１６８５２、１５８７、２２０７、２２２４５、２３８７、５２９０８、６９１１２、１４９９０、１８５４７、１１５、５７９、１５９８５、１５６２５、７６０、１８６０３、２３９５、２５５４、８６７５、３２７２０、４８０９、１４３０３、１６８１６、１７８２７、３２６２０、５７７、６１９、１４２３、２１５８、８２６３、１５４０２、１６２０９、１６３８６、２１１６５、３０９１１、４１８９７、１６４３、２５４３、９６２６、１３２３１、３２４０９、８４２６０、２８８２、８２０３、３２６７８または５５０５３を用いて泌尿器科障害を処置するための方法および組成物
EP1603585A2 (en) 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
WO2004092338A2 (en) * 2003-04-11 2004-10-28 Diadexus, Inc. Compositions, splice variants and methods relating to cancer specific genes and proteins
CN105316405A (zh) * 2003-07-17 2016-02-10 环太平洋生物技术有限公司 用于胃癌检测的标记物
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
US20120077703A1 (en) * 2003-11-03 2012-03-29 Lars Dyrskjot Andersen Expression of MBNL2 and Other Genes Associated with Bladder Cancer Progression
US20130122504A1 (en) * 2011-11-14 2013-05-16 Lars Dyrskjot Andersen Expression Levels of COL4A3BP and other Markers Correlating with Progression or Non-Progression of Bladder Cancer
US9499864B2 (en) * 2003-11-03 2016-11-22 Aab Patent Holding Aps Expression of FABP4 and other genes associated with bladder cancer progression
US20120082994A1 (en) * 2003-11-03 2012-04-05 Lars Dyrskjot Andersen Expression Levels of COL4A1 and other Markers Correlating with Progression or Non-Progression of Bladder Cancer
SI1725249T1 (sl) 2003-11-06 2014-04-30 Seattle Genetics, Inc. Spojine monometilvalina, sposobne konjugacije na ligande
US7427670B2 (en) * 2003-12-19 2008-09-23 Cytochroma Inc. Cytochrome P450 24 (CYP24) monoclonal antibody and methods and uses thereof
EP1584684A1 (en) 2004-02-20 2005-10-12 Samsung Electronics Co., Ltd. Breast cancer related protein, gene encoding the same, and method of diagnosing breast cancer using the protein and gene
KR100763902B1 (ko) * 2004-02-20 2007-10-05 삼성전자주식회사 유방암 특이적 단백질, 그를 코딩하는 유전자, 및 상기단백질 또는 유전자를 이용한 유방암의 진단 방법
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US7939251B2 (en) * 2004-05-06 2011-05-10 Roche Molecular Systems, Inc. SENP1 as a marker for cancer
DE102004023187A1 (de) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
AU2013206612B2 (en) * 2004-05-11 2016-04-28 Biontech Ag Identification of surface-associated antigens for tumor diagnosis and therapy
AU2012200098B2 (en) * 2004-05-11 2014-05-08 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumour diagnosis and therapy
US20080268476A1 (en) * 2004-05-12 2008-10-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nectin 4 (N4) as a Marker for Cancer Prognosis
EP2286844A3 (en) 2004-06-01 2012-08-22 Genentech, Inc. Antibody-drug conjugates and methods
EP1759020A4 (en) * 2004-06-21 2008-04-16 Exelixis Inc ACACS AS MODIFICATORS OF THE IGF PATH AND METHOD OF USE
KR102163550B1 (ko) * 2004-07-23 2020-10-12 퍼시픽 에지 리미티드 방광암 검출용 소변 표지
AU2015255158A1 (en) * 2004-07-23 2015-12-03 Pacific Edge Limited Urine markers for detection of bladder cancer
KR20070051286A (ko) * 2004-07-23 2007-05-17 퍼시픽 에지 바이오테크놀로지 엘티디. 방광암 검출용 소변 표지
WO2006034488A2 (en) 2004-09-23 2006-03-30 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
JPWO2006035515A1 (ja) * 2004-09-28 2008-05-15 平 前川 膀胱表在性癌の治療又は予防用医薬組成物、及びその利用
EP1842065B1 (en) 2005-01-28 2010-12-01 Children's Medical Center Corporation Methods for diagnosis and prognosis of bladder cancer
EP2295601A1 (en) * 2005-02-10 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
DK2529619T3 (en) 2005-02-17 2016-01-11 Biogen Ma Inc Treatment of neurological disorders
DE102005013846A1 (de) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
EP1885388B1 (en) 2005-05-10 2013-09-11 Biogen Idec MA Inc. Treating and evaluating inflammatory disorders
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
CN101273145A (zh) * 2005-07-28 2008-09-24 肿瘤疗法科学股份有限公司 癌症相关基因rasgef1a
CA2621303A1 (en) * 2005-09-01 2007-03-08 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators
JP2009508493A (ja) * 2005-09-19 2009-03-05 ベリデックス・エルエルシー すい臓がんを診断するための方法
EP1775590A1 (en) * 2005-10-11 2007-04-18 Laboratorios S.A.L.V.A.T., S.A. Non-invasive in vitro method to detect transitional cell carcinoma of the bladder
NZ568015A (en) * 2005-12-08 2012-03-30 Medarex Inc Human monoclonal antibodies to O8E
WO2007067730A2 (en) 2005-12-08 2007-06-14 Medarex, Inc. Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use
WO2007090076A2 (en) * 2006-01-27 2007-08-09 Tripath Imaging, Inc. Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor
NZ545243A (en) 2006-02-10 2009-07-31 Pacific Edge Biotechnology Ltd Urine gene expression ratios for detection of cancer
DK1989231T3 (en) 2006-03-21 2015-08-24 Genentech Inc COMBINATION THERAPY INVOLVING ALFA5BETA1 antagonists
US20070237713A1 (en) 2006-04-04 2007-10-11 Fan Rong A PCan065 Antibody Compositions and Methods of Use
US20070259361A1 (en) * 2006-04-11 2007-11-08 Corixa Corporation Methods, compositions, and kits for the detection and monitoring of bladder cancer
EP2010652B1 (en) 2006-04-25 2020-02-26 Future Medical Diagnostics Co., Ltd A protein, an antibody and measurement of the protein
WO2007134132A2 (en) * 2006-05-12 2007-11-22 Genentech, Inc. Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors
EP1867995A1 (en) * 2006-06-15 2007-12-19 Cézanne S.A.S. In vitro method for diagnosing and monitoring metastasized bladder cancer using the determination of MMP-7 in the circulation of patients
US7851144B2 (en) * 2006-08-18 2010-12-14 The University Of Washington Compositions and methods for detecting cancer
EP2118135A1 (en) * 2006-10-16 2009-11-18 Bayer Schering Pharma AG Crtac as a biomarker, therapeutic and diagnostic target
KR100837341B1 (ko) 2006-11-10 2008-06-12 경북대학교 산학협력단 방광암 표적용 펩타이드 및 이의 용도
WO2008091781A1 (en) * 2007-01-22 2008-07-31 Mayo Foundation For Medical Education And Research Reducing tumor growth
ES2323927B1 (es) * 2007-03-30 2010-05-14 Laboratorios Salvat, S.A. Metodo in vitro no invasivo para detectar carcinoma transicional de vejiga.
US7973138B2 (en) 2007-09-26 2011-07-05 Genentech, Inc. Antibodies
CN102899415B (zh) * 2007-11-30 2014-12-10 基因特力株式会社 使用膀胱癌特异性甲基化标记基因的膀胱癌诊断试剂盒和芯片
US9089540B2 (en) * 2008-01-31 2015-07-28 Keio University Method for determination of sensitivity to anti-cancer agent
MX341747B (es) * 2008-02-29 2016-08-31 Monsanto Technology Llc Evento de maiz mon87460 y composiciones y metodos para detectarlo.
US20090239756A1 (en) * 2008-03-18 2009-09-24 Syddansk Universitet Predictors for metastasis of breast cancer
ES2532635T3 (es) 2008-07-15 2015-03-30 Genentech, Inc. Conjugados de antraciclina, proceso para su preparación y su uso como compuestos antitumorales
EP2214019A1 (en) * 2009-01-28 2010-08-04 Externautics S.p.A. Tumor markers and methods of use thereof
EP2524928A1 (en) * 2011-05-18 2012-11-21 Atlas Antibodies AB RBM3 in bladder cancer
PE20120770A1 (es) 2009-03-25 2012-07-10 Genentech Inc ANTICUERPOS ANTI alfa5ß1 CON ACTIVIDAD SOBRE GLIOBLASTOMAS
AU2010292172A1 (en) 2009-09-09 2012-05-03 Centrose, Llc Extracellular targeted drug conjugates
JP2013512000A (ja) * 2009-12-01 2013-04-11 コンペンディア バイオサイエンス， インコーポレイテッド 癌の分類
PE20130342A1 (es) 2010-04-15 2013-04-20 Spirogen Sarl Pirrolobenzodiacepinas y conjugados de las mismas
EP2579897A1 (en) 2010-06-08 2013-04-17 Genentech, Inc. Cysteine engineered antibodies and conjugates
TWI814373B (zh) 2010-09-29 2023-09-01 美商艾澤西公司 與191p4d12蛋白結合之抗體藥物共軛物(adc)
NZ589251A (en) * 2010-11-12 2014-07-25 Pacific Edge Ltd Novel marker for detection of bladder cancer
WO2012067899A2 (en) * 2010-11-15 2012-05-24 Vanderbilt University Foxa1 as a marker for invasive bladder cancer
ES2544608T3 (es) 2010-11-17 2015-09-02 Genentech, Inc. Conjugados de anticuerpo y de alaninil-maitansinol
WO2012154983A2 (en) 2011-05-10 2012-11-15 Biocare Medical, Llc Systems and methods for anti-pax8 antibodies
CA2833212C (en) 2011-05-12 2020-06-09 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
WO2012178087A1 (en) * 2011-06-22 2012-12-27 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of bladder cancer
HUE025661T2 (en) 2011-10-14 2016-04-28 Medimmune Ltd Pyrrolobenzodiazepines and their conjugates
US20130115599A1 (en) * 2011-11-08 2013-05-09 Medical Diagnostic Laboratories, Llc Increased cip2a expression and bladder cancer in humans
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
US20140045196A1 (en) * 2012-08-13 2014-02-13 University Of Tokyo Methods of prognosis and diagnosis of cancer
AU2013305534B2 (en) 2012-08-23 2018-05-31 Agensys, Inc. Antibody drug conjugates (ADC) that bind to 158P1D7 proteins
ES2682345T3 (es) 2012-09-27 2018-09-20 Biocare Medical, Llc Sistemas y procedimientos de anticuerpos antiuroplaquina II
NZ707534A (en) 2012-10-12 2018-08-31 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
NZ707486A (en) 2012-10-12 2018-09-28 Adc Therapeutics Sa Pyrrolobenzodiazepine - anti-psma antibody conjugates
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
DK2906251T3 (da) 2012-10-12 2017-11-20 Adc Therapeutics Sa Pyrrolobenzodiazepin-anti-CD22-antistofkonjugater
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
MX364328B (es) 2012-10-12 2019-04-23 Medimmune Ltd Conjugados del anticuerpo pirrolobenzodiazepina.
PL2766048T3 (pl) 2012-10-12 2015-05-29 Medimmune Ltd Pirolobenzodiazepiny i ich koniugaty
US10429390B2 (en) 2012-12-18 2019-10-01 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
CA2894959C (en) 2012-12-21 2022-01-11 Spirogen Sarl Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
CN110452242A (zh) 2012-12-21 2019-11-15 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
JP6445467B2 (ja) 2013-02-28 2019-01-09 バイオケア メディカル， エルエルシー 抗ｐ４０抗体システムおよび方法
WO2014138396A1 (en) * 2013-03-06 2014-09-12 Cepheid Methods of detecting bladder cancer
CN105142674B (zh) 2013-03-13 2018-11-13 麦迪穆有限责任公司 吡咯并苯并二氮杂卓和其结合物
US20160031887A1 (en) 2013-03-13 2016-02-04 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
AU2014244245C1 (en) 2013-03-13 2018-04-19 Genentech, Inc. Pyrrolobenzodiazepines and conjugates thereof
EA201690195A1 (ru) 2013-08-12 2016-05-31 Дженентек, Инк. Конъюгатные соединения антитело-лекарство на основе димера 1-(хлорметил)-2,3-дигидро-1h-бензо[e]индола и способы применения и лечения
DK3052522T3 (da) 2013-10-03 2020-02-24 Biocare Medical Llc Anti-sox 10 antistofsystemer og -fremgangsmåder
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015069187A1 (en) * 2013-11-05 2015-05-14 Agency For Science, Technology And Research Bladder Carcinoma Biomarkers
EP3082875B1 (en) 2013-12-16 2020-11-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
CN105873614B (zh) 2013-12-16 2020-10-30 基因泰克公司 肽模拟化合物及其抗体-药物缀合物
MX2016007578A (es) 2013-12-16 2016-10-03 Genentech Inc Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo [e] indol, y metodos de uso y tratamiento.
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
AR101844A1 (es) 2014-09-12 2017-01-18 Genentech Inc Anticuerpos y conjugados modificados genéticamente con cisteína
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
WO2016040825A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
JP2017533887A (ja) 2014-09-17 2017-11-16 ジェネンテック， インコーポレイテッド ピロロベンゾジアゼピン類及びその抗体ジスルフィドコンジュゲート
KR20170101895A (ko) 2014-11-25 2017-09-06 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항체 접합체
KR20170086121A (ko) 2014-12-03 2017-07-25 제넨테크, 인크. 4급 아민 화합물 및 그의 항체-약물 접합체
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP6943872B2 (ja) 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド 多重全抗体及び抗体複合体化薬物定量化アッセイ
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
PL3458101T3 (pl) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
JP7022080B2 (ja) 2016-05-27 2022-02-17 ジェネンテック， インコーポレイテッド 部位特異的抗体－薬物複合体の特徴付けのための生化学分析的方法
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
EP3496763A1 (en) 2016-08-11 2019-06-19 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
WO2018065501A1 (en) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Methods for preparing antibody drug conjugates
SG11201903008YA (en) 2016-10-07 2019-05-30 Univ Texas Hla-restricted vgll1 peptides and use thereof
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
AU2018217926B2 (en) 2017-02-08 2019-10-03 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
EP3612537B1 (en) 2017-04-18 2022-07-13 Medimmune Limited Pyrrolobenzodiazepine conjugates
US20200129637A1 (en) 2017-04-20 2020-04-30 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
KR102442736B1 (ko) 2017-06-14 2022-09-16 에이디씨 테라퓨틱스 에스에이 항-cd19 adc의 투여를 위한 투약량 체제
JP7220203B2 (ja) 2017-08-18 2023-02-09 メドイミューン・リミテッド ピロロベンゾジアゼピン複合体
IL273387B2 (en) 2017-09-20 2023-10-01 Ph Pharma Co Ltd Thylanstatin analogs
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
EP3870235A1 (en) 2018-10-24 2021-09-01 F. Hoffmann-La Roche AG Conjugated chemical inducers of degradation and methods of use
CN113227119A (zh) 2018-12-10 2021-08-06 基因泰克公司 用于与含Fc的蛋白质进行位点特异性缀合的光交联肽
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
WO2024138128A2 (en) 2022-12-23 2024-06-27 Genentech, Inc. Cereblon degrader conjugates, and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218529B1 (en) * 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
AU7474696A (en) * 1995-11-03 1997-05-22 Robert R. Bahnson Bladder nuclear matrix proteins and their use in detecting and treating cell proliferative disorders

Also Published As

Publication number Publication date
AU2002316576A1 (en) 2003-01-21
US20040076955A1 (en) 2004-04-22
EP1408811A2 (en) 2004-04-21
JP2005514908A (ja) 2005-05-26
WO2003003906A3 (en) 2003-11-06
WO2003003906A2 (en) 2003-01-16
CA2453098A1 (en) 2003-01-16

Similar Documents

Publication Publication Date Title
MXPA04000080A (es) Metodos de diagnostico de cancer en la vejiga, composiciones y metodos de rastreo de moduladores de cancer en la vejiga.
WO2002030268A3 (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
WO2002059377A3 (en) Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
WO2003025138A3 (en) Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
WO2002098358A3 (en) Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer
WO2003042661A3 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2002102235A3 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
WO2004048938A3 (en) Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
WO2004063355A3 (en) Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
AU2001253079A1 (en) Methods, compositions and kits for the detection and monitoring of breast cancer
EP2003196A3 (en) Compositions and methods for treating and diagnosing cancer
TW200512298A (en) Method of diagnosing breast cancer
WO2004008147A3 (en) Diagnosis and prevention of cancer cell invasion
MXPA02000192A (es) Composiciones y metodos para la terapia y diagnostico de cancer de pulmon.
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
WO2004052276A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
WO2001096390A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2004097052A3 (en) Methods for prognosis and treatment of solid tumors
TW200626900A (en) Wnt proteins and detection and treatment of cancer
Vail et al. Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder
GB0124145D0 (en) Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease
WO2005058251A3 (en) Hla-dr-specific antibodies, compositions and methods
WO2003076610A3 (fr) Variants de kallikrein-2 et kallikrein-3 humaines et leurs utilisations
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer